Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

Abstract

Internal tandem duplication (ITD) of the juxtamembrane (JM) domain of FLT3 is the most frequent mutation in human acute myeloid leukemia, and is significantly associated with leukocytosis and a poor prognosis. Previously we reported that FLT3 with ITD (FLT3/ITD) formed a homodimer and was autophosphorylated on tyrosine residues, while the mechanism remains unclear. In this study, we elucidated the role of the JM domain in FLT3 activation. Mutant FLT3 with not only ITD but also an elongating or shortening JM domain transformed murine IL3-dependent myeloid progenitor cell line 32D regardless of the tyrosine residues in the JM domain. These mutant FLT3s were constitutively tyrosine phosphorylated and activated signal-transduction molecules such as SHC, MAP kinase and STAT5a. Notably, co-transfection of the truncated FLT3/ITD lacking kinase and C-terminal domains with the wild type (Wt)-FLT3 into 32D cells resulted in the autonomous proliferation. In these cells, truncated FLT3/ITD generated a hetero-complex with Wt-FLT3 and Wt-FLT3 was constitutively tyrosine phosphorylated. These findings indicate that the FLT3 JM domain plays an important role in receptor activation, and that the length-mutated JM domain induces ligand-independent receptor activation but also activates Wt-FLT3 in a trans-manner.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Boissan M, Feger F, Guillosson JJ, Arock M . 2000 J. Leuk. Biol. 67: 135–148

  • Buchner J . 1999 Trends Biochem. Sci. 24: 136–141

  • Feiken E, van Etten I, Gebbink MF, Moolenaar WH, Zondag GC . 2000 J. Biol. Chem. 275: 15350–15356

  • Freeman BC, Morimoto RI . 1996 EMBO J. 15: 2969–2979

  • Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y . 1993 J. Clin. Invest. 92: 1736–1744

  • Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T . 2000 Oncogene 19: 624–631

  • Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, Taniwaki M, Kashima K, Fujii H, Abe T, Misawa S . 1997 Leukemia 11: 1442–1446

  • Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, Onodera N, Watanabe A, Kikuta A, Tanaka A, Asami K, Sekine I, Mugishima H, Nishimura Y, Koizumi S, Horikoshi Y, Mimaya J, Ohta S, Nishikawa K, Iwai A, Shimokawa T, Nakayama M, Kawakami K, Gushiken T, Hyakuna N, Katano N, Tsurusawa M, Fujimoto T . 1999 Leukemia 13: 38–43

  • Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, Matsuzawa Y . 1995 Blood 85: 790–798

  • Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R . 1999 Blood 93: 3074–3080

  • Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S, Tamura J, Shimazaki C, Matsue K, Kobayashi H, Arima N, Suzuki R, Morishita H, Saito H, Ueda R, Ohno R . 1997 Leukemia 11: 1447–1452

  • Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T . 1998 Leukemia 12: 1333–1337

  • Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J, Kato K, Kojima S, Matsuyama T . 1999 Med. Pediatr. Oncol. 33: 525–529

  • Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch KA . 1998 Mol. Cell. Biol. 18: 2089–2099

  • Lam LP, Chow RY, Berger SA . 1999 Biochem. J. 338: 131–138

  • Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ . 1999 J. Biol. Chem. 274: 13399–13402

  • Marchetto S, Fournier E, Beslu N, Aurran-Schleinitz T, Dubreuil P, Borg JP, Birnbaum D, Rosnet O . 1999 Leukemia 13: 1374–1382

  • Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR . 1991 Cell 65: 1143–1152

  • Mayer MP, Bukau B . 1999 Curr. Biol. 9: R322–R325

  • Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP . 2001 Blood 97: 89–94

  • Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, Gruning W, Kratz-Albers K, Serve S, Steur C, Buchner T, Kienast J, Kanakura Y, Berdel WE, Serve H . 2000 Blood 96: 3907–3914

  • Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S . 1996 Leukemia 10: 1911–1918

  • Robertson SC, Tynan J, Donoghue D . 2000 Trends Genet. 16: 368–

  • Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE . 2000 Leukemia 14: 675–683

  • Tsujimura T . 1996 Pathol. Int. 46: 933–938

  • Tsujimura T, Hashimoto K, Kitayama H, Ikeda H, Sugahara H, Matsumura I, Kaisho T, Terada N, Kitamura Y, Kanakura Y . 1999 Blood 93: 1319–1329

  • Weiss A, Schlessinger J . 1998 Cell 94: 277–280

  • Wiech H, Buchner J, Zimmerman R, Jakob U . 1992 Nature 358: 169–170

  • Williams JC, Wierenga RK, Saraste M . 1998 Trends Biochem. Sci. 23: 179–184

  • Xu F, Taki T, Yang HW, Hanada R, Hongo T, Ohnishi H, Kobayashi M, Bessho F, Yanagisawa M, Hayashi Y . 1999 Br. J. Haematol. 105: 155–162

  • Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y, Naoe T . 1997 Leukemia 11: 1605–1609

  • Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, Leonard WJ, Broxmeyer HE . 2000 J. Exp. Med. 192: 719–728

  • Zhang S, Mantel C, Broxmeyer HE . 1999 J. Leukoc. Biol. 65: 372–380

  • Zhao M, Kiyoi H, Yamamoto Y, Ito M, Towatari M, Omura S, Kitamura T, Ueda R, Saito H, Naoe T . 2000 Leukemia 14: 374–378

Download references

Acknowledgements

This work was supported by Grants-in-Aid from the Japanese Ministry of Health, Labour and Welfare, the Ministry of Education, Culture, Sports, Science and Technology, Novartis Foundation for the Promotion of Science and Uehara Memorial Foundation. We thank Dr Oliver Rosnet, Dr Toshio Kitamura and Kirin Brewery Co. Ltd. for providing us with materials, and Dr Manabu Ninomiya, Ms Yoko Kudo and Ms Yoko Tagawa for technical and secretarial assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hitoshi Kiyoi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kiyoi, H., Ohno, R., Ueda, R. et al. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21, 2555–2563 (2002). https://doi.org/10.1038/sj.onc.1205332

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205332

Keywords

This article is cited by

Search

Quick links